Furthermore, patients included in the VICTORIA study exhibited higher values of NT-proBNP (2816 pg/mL) compared to the PARADIGM-HF and DAPA-HF trials (1608 and 1437 pg/mL respectively) and a greater number of patients (41%) were in NYHA class III- IV compared to the 25% and 32% of the patients in the PARADIGM-HF and DAPA-HF trials, respectively [14,24,25,26]. The gene discussed is NPPB; the disease is hydrops fetalis.